BioSpace News Archive

NovaGo Therapeutics, a development stage biotech company with a proprietary platform to stimulate blood vessel and nerve growth, today announced the appointment of Ian Metcalfe as the company’s Chief Executive Officer.

Zogenix, Inc. (Nasdaq: ZGNX) today announced its intention to offer, subject to market and other conditions, $200,000,000 aggregate principal amount of convertible senior notes due 2027 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Zogenix also expects to grant the initial purchasers of the notes an option to purchase, for set

MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the publication of a manuscript in Blood , a journal of the American Society of Hematology, which highlights interim results of an ongoing Phase 1/2 clinical trial of flotetuzumab in patients with acute myeloid leukemia (AML). Flotetu

Health Care Service Corporation (HCSC) announced Catherine Nelson as the company’s Chief Legal officer, effective immediately. In her new role Nelson will lead the company’s legal strategy, including overseeing internal and outside counsel support of all regulatory, litigation, contract, transactional, and governance matters affecting HCSC and its operating units.

Management presentation Wednesday, September 23 at 10:50 a.m. EDT

Predictive Oncology now has a total of 96 unique Patient Derived Cells (PDCs) from Ovarian Cancer Patients.

The Association for Value-Based Cancer Care (AVBCC) is proud to announce the highly esteemed Co-Chairs for the upcoming 10th Annual AVBCC Summit. As in years past, the Co-Chairs are a hand-selected powerhouse of leaders in the cancer care ecosystem. The Co-Chairs are intimately involved with the selection of more than 150 fa

Indee Labs is a biotechnology company developing the µVS Delivery SystemTM for non-viral intracellular or gene delivery.

HekaBio K.K. (hereafter: HekaBio) and Cosmo Public Relations Corporation (hereafter: Cosmo) have announced that Cosmo has made an investment in HekaBio and that the companies have entered into a strategic partnership to increase awareness of and accessibility to emerging innovations in the bioscience field that will aid in meeting the needs of patients and society as a whole.

Wisconsin Pharmacal Company, LLC has announced that Andrew Wundrock has been appointed to the position of President of the company effective September 2020.